Proteomic analysis reveals down-regulation of surfactant protein B in murine type II pneumocytes infected with influenza A virus

Abstract Infection of type II alveolar epithelial (ATII) cells by influenza A viruses (IAV) correlates with severe respiratory disease in humans and mice. To understand pathogenic mechanisms during IAV infection of ATII cells, murine ATII cells were cultured to maintain a differentiated phenotype, i...

Full description

Saved in:
Bibliographic Details
Published inVirology (New York, N.Y.) Vol. 483; no. C; pp. 96 - 107
Main Authors Kebaabetswe, Lemme P, Haick, Anoria K, Gritsenko, Marina A, Fillmore, Thomas L, Chu, Rosalie K, Purvine, Samuel O, Webb-Robertson, Bobbie-Jo, Matzke, Melissa M, Smith, Richard D, Waters, Katrina M, Metz, Thomas O, Miura, Tanya A
Format Journal Article
LanguageEnglish
Published United States Elsevier Inc 01.09.2015
Elsevier
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Abstract Infection of type II alveolar epithelial (ATII) cells by influenza A viruses (IAV) correlates with severe respiratory disease in humans and mice. To understand pathogenic mechanisms during IAV infection of ATII cells, murine ATII cells were cultured to maintain a differentiated phenotype, infected with IAV-PR8, which causes severe lung pathology in mice, and proteomics analyses were performed using liquid chromatography–mass spectrometry. PR8 infection increased levels of proteins involved in interferon signaling, antigen presentation, and cytoskeleton regulation. Proteins involved in mitochondrial membrane permeability, energy metabolism, and chromatin formation had reduced levels in PR8-infected cells. Phenotypic markers of ATII cells in vivo were identified, confirming the differentiation status of the cultures. Surfactant protein B had decreased levels in PR8-infected cells, which was confirmed by immunoblotting and immunofluorescence assays. Analysis of ATII cell protein profiles will elucidate cellular processes in IAV pathogenesis, which may provide insight into potential therapies to modulate disease severity.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
USDOE Office of Science (SC), Biological and Environmental Research (BER)
Current Affiliation: Department of Biology and Biotechnological Sciences Botswana International University of Science and Technology, Palapye, Botswana
Current Affiliation: Department of Medicine, University of Washington, Seattle, WA
Current Affiliation: Unilever, Englewood Cliffs, NJ
ISSN:0042-6822
1096-0341
DOI:10.1016/j.virol.2015.03.045